Explaining urokinase type plasminogen activator inhibition by amino-5-hydroxybenzimidazole and two naphthamidine-based compounds through quantum biochemistry

Physical Chemistry Chemical Physics : PCCP
Christian Solis-CaleroValder N Freire

Abstract

Urokinase plasminogen activator (uPA) is a biomarker and therapeutic target for several cancer types whose inhibition has been shown to slow tumor growth and metastasis. In this work, crystallographic data of uPA complexed with distinct ligands (PDB id: 1SQA, 1SQO, and 1FV9) were used to perform quantum biochemistry calculations based on the framework of density functional theory (DFT) and within the molecular fractionation with conjugated caps (MFCC) scheme. Our calculations revealed a total energy interaction of -107.30, -99.5, and -35.30 kcal mol-1 for two naphthamidine-based compounds (Ul1 and UI2) and 2-amino-5-hydroxybenzimidazole (172), respectively, which are in good agreement with known inhibitory experiments. Residues Asp189, Ser190, Cys191-Cys220, Gln192, Trp 215, Gly216, and Gly219 were identified as the main interacting amino acid residues with interaction energy contributions lower than -4.0 kcal mol-1 for uPA/UI1 and UPA/UI2 complexes. In the case of compound 172, our calculations have shown that the most important interactions occur with residues Asp189, Cys191-Cys220, and Ser190. Our results highlight the relevance of the protonation state of ligands and residues and that the naphthamidine scaffold of UI1 and U...Continue Reading

References

Apr 20, 1967·Biochemical and Biophysical Research Communications·I Schechter, A Berger
Jan 3, 1995·Proceedings of the National Academy of Sciences of the United States of America·B M MuellerW E Laug
Jun 1, 1993·Proceedings of the National Academy of Sciences of the United States of America·C W CrowleyA D Levinson
May 22, 1998·Journal of Molecular Biology·Y Mandel-GutfreundV B Zhurkin
Sep 30, 1998·Proceedings of the National Academy of Sciences of the United States of America·A T MaynardD G Covell
Jul 2, 1999·Journal of Surgical Oncology·M J DuffyN O'Higgins
Oct 29, 2000·Journal of Medicinal Chemistry·P J HajdukS W Fesik
Aug 2, 2001·Biochemistry·V KlinghoferV L Giranda
Dec 1, 2001·Expert Opinion on Biological Therapy·B MuehlenwegN Harbeck
Sep 5, 2002·Journal of the American Chemical Society·Mutasem Omar SinnokrotC David Sherrill
Oct 2, 2002·The Journal of Organic Chemistry·Jordi RibasModesto Orozco
Oct 9, 2002·Current Pharmaceutical Design·T W RockwayV L Giranda
Feb 13, 2003·Journal of the American Chemical Society·Artëm Masunov, Themis Lazaridis
Mar 20, 2003·Angewandte Chemie·Emmanuel A MeyerFrançois Diederich
Jul 23, 2003·Current Pharmaceutical Design·Todd W Rockway, Vincent L Giranda
Apr 13, 2004·Proceedings of the National Academy of Sciences of the United States of America·Andrew I SuJohn B Hogenesch
Jul 23, 2004·The Journal of Chemical Physics·Da W ZhangJohn Z H Zhang
Sep 9, 2004·Chemical Society Reviews·Mijoon LeeShahriar Mobashery
Dec 8, 2004·Bioorganic & Medicinal Chemistry Letters·Milan BrunckoVincent L Giranda
Jun 16, 2005·Journal of the American Chemical Society·Scott L CockroftChristopher J Urch
Dec 14, 2005·Journal of Molecular Modeling·Simona Cotesta, Martin Stahl
Apr 14, 2006·The Journal of Physical Chemistry. a·Young Choon Park, Jae Shin Lee
May 10, 2006·The Journal of Biological Chemistry·Jean-François CoutureRaymond C Trievel
Jan 25, 2007·Journal of the American Chemical Society·Daniel J MandellMatthew P Jacobson
Jul 31, 2007·Cancer Treatment Reviews·Y Li, P J Cozzi
Oct 16, 2007·Bioorganic & Medicinal Chemistry·Ashish Kumar Tewari, Rashmi Dubey
Feb 10, 2009·Current Cancer Drug Targets·Salvatore UlisseMassimino D'Armiento
Mar 5, 2009·Physical Review Letters·Alexandre Tkatchenko, Matthias Scheffler
Nov 12, 2009·Future Oncology·Ahmed H MekkawyMohammad H Pourgholami
Apr 21, 2010·Expert Opinion on Investigational Drugs·Ralf HildenbrandPhilipp Stroebel
Nov 26, 2010·The Journal of Physical Chemistry. B·Peter I Nagy, Paul W Erhardt
Jan 29, 2011·BMC Structural Biology·Michał RostkowskiJan H Jensen
Jun 29, 2011·Current Drug Targets·Jacky Chi Ki NgoMingdong Huang
Oct 12, 2011·The Journal of Physical Chemistry. B·Olga Yuzlenko, Themis Lazaridis
Dec 14, 2011·Physical Chemistry Chemical Physics : PCCP·Roner F da CostaEudenilson L Albuquerque

❮ Previous
Next ❯

Methods Mentioned

BETA
X-ray
protein folding

Software Mentioned

DMOL3
PyMol
COSMO
BioSolveIT
ChemAxon
LeadIT
PROPKA
AMBER

Related Concepts

Related Feeds

Anthelmintics

Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.